Wolfgang Bargmann (1906-1978) and Heinrich von Hayek (1900-1969): careers in anatomy continuing through German National Socialism to postwar leadership.

S. Hildebrandt

DOI: https://doi.org/10.1016/j.aanat.2013.04.003

2013-07-01

Annals of Anatomy

Abstract:

What problem does this paper attempt to address?

KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis

Lijun Du,John J. Kim,Jinhua Shen,Binrui Chen,Ning Dai

DOI: https://doi.org/10.18632/oncotarget.14549

2017-01-01

Oncotarget

Abstract:Although KRAS and TP53 mutations are common in both inflammatory bowel disease-associated colorectal cancer (IBD-CRC) and sporadic colorectal cancer (S-CRC), molecular events leading to carcinogenesis may be different. Previous studies comparing the frequency of KRAS and TP53 mutations in IBD-CRC and S-CRC were inconsistent. We performed a meta-analysis to compare the presence of KRAS and TP53 mutations among patients with IBD-CRC, S-CRC, and IBD without dysplasia. A total of 19 publications (482 patients with IBD-CRC, 4,222 with S-CRC, 281 with IBD without dysplasia) met the study inclusion criteria. KRAS mutation was less frequent (RR=0.71, 95% CI 0.56-0.90; P=0.004) while TP53 mutation was more common (RR=1.24, 95% CI 1.10-1.39; P<0.001) in patients with IBD-CRC compared to S-CRC. Both KRAS (RR=3.09, 95% CI 1.47-6.51; P=0.003) and TP53 (RR=2.15, 95% CI 1.07-4.31 P=0.03) mutations were more prevalent in patients with IBD-CRC compared to IBD without dysplasia. In conclusion, IBD-CRC and S-CRC appear to have biologically different molecular pathways. TP53 appears to be more important than KRAS in IBD-CRC compared to S-CRC. Our findings suggest possible roles of TP53 and KRAS as biomarkers for cancer and dysplasia screening among patients with IBD and may also provide targeted therapy in patients with IBD-CRC.
An Overview of Molecular Profiles in Ulcerative Colitis–Related Cancer

Min Xue,Liuhong Shi,Weijia Wang,Shujie Chen,Liangjing Wang

DOI: https://doi.org/10.1093/ibd/izy221

2018-01-01

Inflammatory Bowel Diseases

Abstract:Ulcerative colitis (UC) is an independent risk factor of colorectal cancer (CRC). Both genetic and epigentic events induce a unique molecular profile during the development from UC to UC-related CRC (UCRC). These molecular changes play varied roles in DNA repair, immune response, cell metabolism, and interaction with the microbiota during the carcinogenesis process. This review will systmatically discuss the molecular characteristics of UCRC and point out the future perspectives in this research field.
Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management

Shailja C Shah,Steven H Itzkowitz

DOI: https://doi.org/10.1053/j.gastro.2021.10.035

IF: 29.4

Gastroenterology

Abstract:Patients with inflammatory bowel disease (IBD) are at increased risk of developing colorectal cancer (CRC), despite decreases in CRC incidence in recent years. Chronic inflammation is the driver of neoplastic progression, resulting in dysplastic precursor lesions that may arise in multiple areas of the colon through a process of field cancerization. Colitis-associated CRC shares many molecular similarities with sporadic CRC, and preclinical investigations have demonstrated a potential role for the microbiome in concert with the host immune system in the development of colitis-associated colorectal cancer (CAC). Some unique molecular differences occur in CAC, but their role in the pathogenesis and behavior of inflammation-associated cancers remains to be elucidated. Nonconventional types of dysplasia have been increasingly recognized, but their natural history is not well defined, and they have not been incorporated into surveillance algorithms. The concept of cumulative inflammatory burden highlights the importance of considering histologic inflammation over time as an important risk factor for CAC. Dysplasia is arguably the most important risk factor for developing CAC, and advances have been made in the endoscopic detection and removal of precancerous lesions, thereby deferring or avoiding surgical resection. Some of the agents used to treat IBD are chemopreventive. It is hoped that by gaining better control of the underlying inflammation with newer medications and better endoscopic detection and management, a more sophisticated appreciation of clinicopathologic risk factors, and growing awareness of the genetic, immunologic, and environmental causes of colitis- associated neoplasia, that colitis-associated colorectal neoplasia will become even more predictable and manageable in the coming years.
Proximal Gastric Vagotomy without “Drainage”: An Experimental Study

C. A. Hallenbeck,J. Gleysteen

DOI: https://doi.org/10.1097/00000658-197405000-00013

IF: 13.787

1974-05-01

Annals of Surgery

Abstract:
Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention

Marianna Lucafò,Debora Curci,Martina Franzin,Giuliana Decorti,Gabriele Stocco

DOI: https://doi.org/10.3389/fphar.2021.772101

IF: 5.6

2021-10-20

Frontiers in Pharmacology

Abstract:Increased risk of colorectal cancer (CRC) in inflammatory bowel disease (IBD) patients has been attributed to long-standing chronic inflammation, with the contribution of genetic alterations and environmental factors such as the microbiota. Moreover, accumulating data indicate that IBD-associated CRC (IBD-CRC) may initiate and develop through a pathway of tumorigenesis distinct from that of sporadic CRC. This mini-review summarizes the current knowledge of IBD-CRC, focusing on the main mechanisms underlying its pathogenesis, and on the important role of immunomodulators and biologics used to treat IBD patients in interfering with the inflammatory process involved in carcinogenesis.

pharmacology & pharmacy
Molecular Pathogenesis of Colitis-associated Colorectal Cancer: Immunity, Genetics, and Intestinal Microecology

Yue Yin,Jian Wan,Jingmin Yu,Kaichun Wu

DOI: https://doi.org/10.1093/ibd/izad081

2023-10-03

Abstract:Patients with inflammatory bowel disease (IBD) have a high risk for colorectal cancer (CRC). This cancer type, which is strongly associated with chronic inflammation, is called colitis-associated CRC (CAC). Understanding the molecular pathogenesis of CAC is crucial to identify biomarkers necessary for early diagnosis and more effective treatment directions. The accumulation of immune cells and inflammatory factors, which constitute a complex chronic inflammatory environment in the intestinal mucosa, may cause oxidative stress or DNA damage to the epithelial cells, leading to CAC development and progression. An important feature of CAC is genetic instability, which includes chromosome instability, microsatellite instability, hypermethylation, and changes in noncoding RNAs. Furthermore, the intestinal microbiota and metabolites have a great impact on IBD and CAC. By clarifying immune, genetic, intestinal microecology, and other related pathogenesis, CAC may be more predictable and treatable.
Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines

Ross J Porter,Mark J Arends,Antonia M D Churchhouse,Shahida Din

DOI: https://doi.org/10.1093/ecco-jcc/jjab102

2021-06-10

Journal of Crohn's and Colitis

Abstract:Abstract The cumulative impact of chronic inflammation in patients with inflammatory bowel diseases predisposes to the development of inflammatory bowel disease-associated colorectal cancer [IBD-CRC]. Inflammation can induce mutagenesis, and the relapsing–remitting nature of this inflammation, together with epithelial regeneration, may exert selective pressure accelerating carcinogenesis. The molecular pathogenesis of IBD-CRC, termed the ‘inflammation–dysplasia–carcinoma’ sequence, is well described. However, the immunopathogenesis of IBD-CRC is less well understood. The impact of novel immunosuppressive therapies, which aim to achieve deep remission, is mostly unknown. Therefore, this timely review summarizes the clinical context of IBD-CRC, outlines the molecular and immunological basis of disease pathogenesis, and considers the impact of novel biological therapies.
Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications

Gati A Goel,Ahmed Kandiel,Jean Paul Achkar,Bret Lashner

DOI: https://doi.org/10.1038/ajg.2011.51

Abstract:Chronic inflammatory diseases, depending upon the duration and severity, are frequently associated with an increased risk of developing cancer. A classic paradigm is the enhanced risk of colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD). Carcinogenesis is a multifactorial process that involves accumulation of genetic defects, protein modification, and cell-matrix interaction. In this review, we discuss aspects of chronic inflammation in IBD that influence the development of CRC and highlight the key molecular mediators involved in this process. Also, we identify potential targets that could facilitate earlier detection of dysplasia. The targeted manipulation of specific molecules or pathways could provide opportunities for the development of therapeutic and chemopreventive interventions, which may prove effective in arresting the progression of colitis-associated cancer (CAC), with clinical implications.
Consequential rather than ‘significant’ results

S. Bangdiwala

DOI: https://doi.org/10.1080/17457300.2016.1194514

2016-06-22

International Journal of Injury Control and Safety Promotion

Abstract:The American Statistical Association (ASA) in March 2016 released a statement with guidelines for the interpretation of statistical significance and p-values, and their place in sound scientific re...
Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy

Olga Maria Nardone,Irene Zammarchi,Giovanni Santacroce,Subrata Ghosh,Marietta Iacucci

DOI: https://doi.org/10.3390/cancers15082389

2023-04-20

Abstract:Patients affected by inflammatory bowel disease (IBD) have a two-fold higher risk of developing colorectal cancer (CRC) than the general population. IBD-related CRC follows a different genetic and molecular pathogenic pathway than sporadic CRC and can be considered a complication of chronic intestinal inflammation. Since inflammation is recognised as an independent risk factor for neoplastic progression, clinicians strive to modulate and control disease, often using potent therapy agents to achieve mucosal healing and decrease the risk of colorectal cancer in IBD patients. Improved therapeutic control of inflammation, combined with endoscopic advances and early detection of pre-cancerous lesions through surveillance programs, explains the lower incidence rate of IBD-related CRC. In addition, current research is increasingly focused on translating emerging and advanced knowledge in microbiome and metagenomics into personalised, early, and non-invasive CRC screening tools that guide organ-sparing therapy in IBD patients. This review aims to summarise the existing literature on IBD-associated CRC, focusing on new insights into the alteration of the intestinal barrier and the interactions with the gut microbiome as the initial promoter. In addition, the role of OMIC techniques for precision medicine and the impact of the available IBD therapeutic armamentarium on the evolution to CRC will be discussed.
Molecular mechanisms in colitis-associated colorectal cancer

Royce W. Zhou,Noam Harpaz,Steven H. Itzkowitz,Ramon E. Parsons

DOI: https://doi.org/10.1038/s41389-023-00492-0

2023-10-27

Oncogenesis

Abstract:Sustained chronic inflammation of the large intestine leads to tissue damage and repair, which is associated with an increased incidence of colitis-associated colorectal cancer (CAC). The genetic makeup of CAC is somewhat similar to sporadic colorectal carcinoma (sCRC), but there are differences in the sequence and timing of alterations in the carcinogenesis process. Several models have been developed to explain the development of CAC, particularly the "field cancerization" model, which proposes that chronic inflammation accelerates mutagenesis and selects for the clonal expansion of phenotypically normal, pro-tumorigenic cells. In contrast, the "Big Bang" model posits that tumorigenic clones with multiple driver gene mutations emerge spontaneously. The details of CAC tumorigenesis—and how they differ from sCRC—are not yet fully understood. In this Review, we discuss recent genetic, epigenetic, and environmental findings related to CAC pathogenesis in the past five years, with a focus on unbiased, high-resolution genetic profiling of non-dysplastic field cancerization in the context of inflammatory bowel disease (IBD).

oncology
Colorectal cancer in inflammatory bowel disease: review of the evidence

D S Keller,A Windsor,R Cohen,M Chand

DOI: https://doi.org/10.1007/s10151-019-1926-2

Abstract:Inflammatory bowel disease (IBD)-related colorectal cancer (CRC) is responsible for approximately 2% of the annual mortality from CRC overall, but 10-15% of the annual deaths in IBD patients. IBD-related CRC patients are also affected at a younger age than sporadic CRC patients, and have a 5-year survival rate of 50%. Despite optimal medical treatment, the chronic inflammatory state inherent in IBD increases the risk for high-grade dysplasia and CRC, with additional input from genetic and environmental risk factors and the microbiome. Recognizing risk factors, implementing appropriate surveillance, and identifying high-risk patients are key to managing the CRC risk in IBD patients. Chemoprevention strategies exist, and studies evaluating their efficacy are underway. Once dysplasia or invasive cancer is diagnosed, appropriate surgical resection and postoperative treatment and surveillance are necessary. Here, we discuss the current state of IBD-related CRC, prevalence, risk factors, and evidence for surveillance, prophylaxis, and treatment recommendations.
HIV/STI associated risk behaviors among self-identified lesbian, gay, bisexual, and transgender college students in the United States.

L. Lindley,T. Nicholson,Molly B. Kerby,Ning Lu

DOI: https://doi.org/10.1521/AEAP.15.6.413.24039

2003-10-01

AIDS Education and Prevention

Abstract:An Internet survey was conducted during the 2001-2002 academic year to examine the health risk behaviors, including HIV/STI associated behaviors, of self-identified lesbian, gay, bisexual, and transgender (LGBT) college students in the United States. A total of 450 LGBT college students completed the entire online survey. Most respondents attended a 4-year (96.9%), coeducational (98.6%), non-religiously affiliated (87.5%), public (68.6%) institution. Eighty-nine percent reported having sex with someone of the same sex and 45% had multiple (6 or more) sex partners during their lifetime. Most reported using a condom consistently during penile-vaginal (61%) and anal sex (63%). However, only 4% used a condom or other barrier consistently during oral sex and 28% used a condom or other barrier during their last sexual encounter. Injection drug use and needle-sharing behavior was low (2.1% and 1.1%, respectively). Comparisons with heterosexual college students' HIV/STI associated risk behaviors are included. Results may be useful for HIV/STI prevention programs targeting LGBT college students.
Role of Inflammation in the Development of Colorectal Cancer

Sridhar Muthusami,Ileng Kumaran Ramachandran,Kokelavani Nampalli Babu,Sneha Krishnamoorthy,Akash Guruswamy,Lurdes Queimado,Gautam Chaudhuri,Ilangovan Ramachandran

DOI: https://doi.org/10.2174/1871530320666200909092908

Abstract:Chronic inflammation can lead to the development of many diseases, including cancer. Inflammatory bowel disease (IBD) that includes both ulcerative colitis (UC) and Crohnmp's disease (CD) are risk factors for the development of colorectal cancer (CRC). Many cytokines produced primarily by the gut immune cells either during or in response to localized inflammation in the colon and rectum are known to stimulate the complex interactions between the different cell types in the gut environment resulting in acute inflammation. Subsequently, chronic inflammation, together with genetic and epigenetic changes, have been shown to lead to the development and progression of CRC. Various cell types present in the colon, such as enterocytes, Paneth cells, goblet cells, and macrophages, express receptors for inflammatory cytokines and respond to tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), IL-6, and other cytokines. Among the several cytokines produced, TNF-α and IL-1β are the key pro-inflammatory molecules that play critical roles in the development of CRC. The current review is intended to consolidate the published findings to focus on the role of pro-inflammatory cytokines, namely TNF-α and IL-1β, on inflammation (and the altered immune response) in the gut, to better understand the development of CRC in IBD, using various experimental model systems, preclinical and clinical studies. Moreover, this review also highlights the current therapeutic strategies available (monotherapy and combination therapy) to alleviate the symptoms or treat inflammation-associated CRC by using monoclonal antibodies or aptamers to block pro-inflammatory molecules, inhibitors of tyrosine kinases in the inflammatory signaling cascade, competitive inhibitors of pro-inflammatory molecules, and the nucleic acid drugs like small activating RNAs (saRNAs) or microRNA (miRNA) mimics to activate tumor suppressor or repress oncogene/pro-inflammatory cytokine gene expression.
Inflammation and colorectal cancer: colitis-associated neoplasia

Sergei I. Grivennikov

DOI: https://doi.org/10.1007/s00281-012-0352-6

2012-11-16

Seminars in Immunopathology

Abstract:Connection between inflammation and cancer is a rapidly developing field. Epidemiological data suggests that inflammation along with distinct arms of host immune system plays a very important role in the development and progression of many different cancers. Inflammatory bowel disease (IBD) is an important risk factor for the development of colon cancer, namely, colitis-associated cancer (CAC). The molecular mechanisms by which inflammation promotes cancer development are still being uncovered and may differ between CAC and other forms of colorectal cancer. Recent work has shed light on the role of distinct immune cells, cytokines, and other immune mediators in virtually all of the steps of colonic tumorigenesis, including tumor initiation and promotion as well as progression and metastasis. The close proximity of colonic tumors to the myriad of intestinal microbes, as well as instrumental role of microbiota in IBD, introduces microbes as new players capable of triggering inflammation and possibly promoting tumorigenesis. Various mechanisms of CAC tumorigenesis as well as new possible hints for the future approaches for prevention and therapy are discussed in this review.

pathology,immunology
Defending humanistic values.

H. Pardes

DOI: https://doi.org/10.1176/AJP.147.9.1112

IF: 17.7

1990-09-01

American Journal of Psychiatry

Abstract:
Risk factors for colorectal neoplasia in patients with underlying inflammatory bowel disease: a multicenter study.

Xian-Rui Wu,Xiao-Bin Zheng,Yan Huang,Qian Cao,Hong-Jie Zhang,Ying-Lei Miao,Kai-Fang Zou,Min Chen,Fa-Ming Zhang,Qiao Mei,David Gonzalo,Daniela Allende,Pin-Jin Hu,Bo Shen,Xiu-Li Liu,Ping Lan

DOI: https://doi.org/10.1093/gastro/goy039

2019-01-01

Gastroenterology Report

Abstract:Background: This study sought to evaluate the risk factors for the development of colitis-associated neoplasia (CAN) in Chinese patients with inflammatory bowel disease (IBD). Methods: IBD patients who developed CAN between 1999 and 2016 were identified from eight medical centers. In addition to initial pathology evaluation, a CAN diagnosis was confirmed by two expert pathologists. Patients with CAN (n=29) were compared with non-CAN controls (n=87). Matching was performed for gender and IBD type with a ratio of three controls to one subject. Results: Of the 29 patients with CAN, 8 (27.6%) had colorectal cancer (CRC), 20 (69.0%) had a final diagnosis of low-grade dysplasia and 1 (3.4%) had high-grade dysplasia. Multivariate analysis revealed that an older age at the time of IBD diagnosis and a longer IBD duration were independent risk factors for the development of CAN, with odds ratios of 1.09 [95% confidence interval (CI): 1.04-1.14, P<0.001] and 1.14 (95% CI: 1.03-1.27, P=0.013), respectively. Comparison between IBD patients with CRC and those with dysplasia indicated that the former were older at the time of IBD diagnosis (P=0.012) and had longer IBD durations (P=0.019). Conclusions: Older age at the time of IBD diagnosis and longer IBD duration were found to be associated with the development of CAN in IBD patients.
Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer

Kristiina Rajamäki,Aurora Taira,Riku Katainen,Niko Välimäki,Anna Kuosmanen,Roosa-Maria Plaketti,Toni T Seppälä,Maarit Ahtiainen,Erkki-Ville Wirta,Emilia Vartiainen,Päivi Sulo,Janne Ravantti,Suvi Lehtipuro,Kirsi J Granberg,Matti Nykter,Tomas Tanskanen,Ari Ristimäki,Selja Koskensalo,Laura Renkonen-Sinisalo,Anna Lepistö,Jan Böhm,Jussi Taipale,Jukka-Pekka Mecklin,Mervi Aavikko,Kimmo Palin,Lauri A Aaltonen

DOI: https://doi.org/10.1053/j.gastro.2021.04.042

IF: 29.4

Gastroenterology

Abstract:Background & aims: Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder associated with an elevated risk of colorectal cancer (CRC). IBD-associated CRC (IBD-CRC) may represent a distinct pathway of tumorigenesis compared to sporadic CRC (sCRC). Our aim was to comprehensively characterize IBD-associated tumorigenesis integrating multiple high-throughput approaches, and to compare the results with in-house data sets from sCRCs. Methods: Whole-genome sequencing, single nucleotide polymorphism arrays, RNA sequencing, genome-wide methylation analysis, and immunohistochemistry were performed using fresh-frozen and formalin-fixed tissue samples of tumor and corresponding normal tissues from 31 patients with IBD-CRC. Results: Transcriptome-based tumor subtyping revealed the complete absence of canonical epithelial tumor subtype associated with WNT signaling in IBD-CRCs, dominated instead by mesenchymal stroma-rich subtype. Negative WNT regulators AXIN2 and RNF43 were strongly down-regulated in IBD-CRCs and chromosomal gains at HNF4A, a negative regulator of WNT-induced epithelial-mesenchymal transition (EMT), were less frequent compared to sCRCs. Enrichment of hypomethylation at HNF4α binding sites was detected solely in sCRC genomes. PIGR and OSMR involved in mucosal immunity were dysregulated via epigenetic modifications in IBD-CRCs. Genome-wide analysis showed significant enrichment of noncoding mutations to 5'untranslated region of TP53 in IBD-CRCs. As reported previously, somatic mutations in APC and KRAS were less frequent in IBD-CRCs compared to sCRCs. Conclusions: Distinct mechanisms of WNT pathway dysregulation skew IBD-CRCs toward mesenchymal tumor subtype, which may affect prognosis and treatment options. Increased OSMR signaling may favor the establishment of mesenchymal tumors in patients with IBD.
Colorectal Cancer in Patients with Inflammatory Bowel Disease: The True Impact of the Risk

László Herszényi,Loránd Barabás,Pál Miheller,Zsolt Tulassay

DOI: https://doi.org/10.1159/000368447

2014-12-17

Digestive Diseases

Abstract:Patients with long-standing inflammatory bowel disease (IBD) have an increased risk of colorectal cancer (CRC). The association between IBD and CRC is well supported, but reported risk estimates vary widely. Although recent evidence from population-based studies reports a decline in risk, CRC accounts for 10-15% of all deaths in IBD. The potential causes of recent epidemiological trends and the real magnitude of risk of CRC in IBD are subjects of debate. The molecular pathway leading to CRC differs from the classic adenoma-to-CRC sequence. Chronic inflammation contributes to the development of low- and high-grade dysplasia which may further convert into CRC. Patients with a young age at onset, long-standing and extensive colitis with severe inflammatory burden, a family history of sporadic CRC, and concomitant primary sclerosing cholangitis are at greatest risk. The CRC risk in patients with colonic Crohn's disease is similar to that of ulcerative colitis. IBD-associated CRC can frequently be detected at late stages and at a younger age. The long-term prognosis of CRC may be poorer in patients with IBD than in those with sporadic CRC. Regular surveillance colonoscopies may permit earlier detection of CRC, with a corresponding improved prognosis. The interval between surveillance colonoscopies is dependent on each patient's personal risk profile.
The molecular landscape of colitis-associated carcinogenesis

Deborah Saraggi,Matteo Fassan,Claudia Mescoli,Marco Scarpa,Nicola Valeri,Andrea Michielan,Renata D'Incá,Massimo Rugge

DOI: https://doi.org/10.1016/j.dld.2016.12.011

Abstract:In spite of the well-established histopathological phenotyping of IBD-associated preneoplastic and neoplastic lesions, their molecular landscape remains to be fully elucidated. Several studies have pinpointed the initiating role of longstanding/relapsing inflammatory insult on the intestinal mucosa, with the activation of different pro-inflammatory cytokines (TNF-α, IL-6, IL-10, IFN-γ), chemokines and metabolites of arachidonic acid resulting in the activation of key transcription factors such as NF-κB. Longstanding inflammation may also modify the intestinal microbiota, prompting the overgrowth of genotoxic microorganisms, which may act as further cancer promoters. Most of the molecular dysregulation occurring in sporadic colorectal carcinogenesis is documented in colitis-associated adenocarcinoma too, but marked differences have been established in both their timing and prevalence. Unlike sporadic cancers, TP53 alterations occur early in IBD-related carcinogenesis, while APC dysregulation emerges mainly in the most advanced stages of the oncogenic cascade. From the therapeutic standpoint, colitis-associated cancers are associated with a lower prevalence of KRAS mutations than the sporadic variant. Epigenetic changes, including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs, are significantly involved in colitis-associated cancer development and progression. The focus now is on identifying diagnostic and prognostic biomarkers, with a view to ultimately designing patient-tailored therapies.

Wolfgang Bargmann (1906-1978) and Heinrich von Hayek (1900-1969): careers in anatomy continuing through German National Socialism to postwar leadership.

KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis

An Overview of Molecular Profiles in Ulcerative Colitis–Related Cancer

Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management

Proximal Gastric Vagotomy without “Drainage”: An Experimental Study

Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention

Molecular Pathogenesis of Colitis-associated Colorectal Cancer: Immunity, Genetics, and Intestinal Microecology

Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines

Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications

Consequential rather than ‘significant’ results

Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy

Molecular mechanisms in colitis-associated colorectal cancer

Colorectal cancer in inflammatory bowel disease: review of the evidence

HIV/STI associated risk behaviors among self-identified lesbian, gay, bisexual, and transgender college students in the United States.

Role of Inflammation in the Development of Colorectal Cancer

Inflammation and colorectal cancer: colitis-associated neoplasia

Defending humanistic values.

Risk factors for colorectal neoplasia in patients with underlying inflammatory bowel disease: a multicenter study.

Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer

Colorectal Cancer in Patients with Inflammatory Bowel Disease: The True Impact of the Risk

The molecular landscape of colitis-associated carcinogenesis